The Short-term Efficacy Of Intravitreal Avastin (Bevacizumab; Genentech, Inc) In The Treatment Of Idiopathic Choroidal Neovascularization (ICNV)

PURPOSE To evaluate the short-term efficacy and safety of intravitreal Avastin(Bevacizumab; Genentech, Inc) in the treatment of idiopathic choroidal neovascularization( ICNV).Method In this prospective randomized compared intervention study , 40 patients (41 eyes, 32 female 33 eyes, 8 male 8 eyes) were divided into two groups, one is treated group, the other is control group. 17 patients (18 eyes ) were separated into the control group, and the other 23 patients were separated into the treated group. All patients received the treatment of Xueshuantong by peros. Patients in treated group received 1.25mg/0.05ml Avastin each time, injection was performed at an average interval of 4 weeks, Ophthalmic evaluation included Best-correct visual acuity, intraocular pressure, central macular thickness, fundus examinations and complications. All 41 patients were followed 12 months and ophthalmic evaluations were assessed on both treated group and control group.ResultTreated group: The mean best-corrected visual acuity (logMAR) improved from 0.77±0.41 at a baseline to 0.31±0.36 at 12 months. The mean CMT reduced from 348±67μm at a baseline to 228±33μm at 12 months. The absence of CNV leakage was observed in 95.65% eyes at 12 months.Control group: The mean best-corrected visual acuity (logMAR) improved from 0.70±0.48 at a baseline to 0.50±0.32 at 12 months. The mean CMT reduced from 332±72μm at a baseline to 251±39μm at 12 months. The absence of CNV leakage was observed in 50% eyes at 12 months.Compared the results of two groups, we concluded that the visual acuity has a significant improvement in treated group, the difference was statistically significant (P < 0.01), whereas the difference of two groups in the result of mean CMT was not significant either at baseline or at 12 months (P > 0.05) . The difference of absence of CNV leakage in two groups was statistically significant (P < 0.05)at 12 months. No systemic or ocular adverse events were encountered in the treated group.ConclusionShort-term results suggest that intravitreal bevacizumab could reduce the central macular thickness, improve patients' visual acuity and also shorten the course of disease, is safe and well tolerated in idiopathic choroidal neovascularization.